Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC : New Options on the Horizon?
© 2021 Passiglia et al..
The therapeutic targeting of the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) axis marked a milestone in the treatment of non-small cell lung cancer (NSCLC), leading to unprecedented response duration and long-term survival for a relevant subgroup of patients affected by non-oncogene-addicted, metastatic disease. However, the biological heterogeneity as well as the occurrence of innate/acquired resistance are well-known phenomena which significantly affect the therapeutic response to immunotherapy. To date, we are moving towards the second phase of the "immune-revolution", characterized by the advent of new immune-checkpoint inhibitors combinations, aiming to target the main resistance pathways and ultimately increase the number of NSCLC patients who may derive long-term clinical benefit from immunotherapy. In this review, we provide an updated and comprehensive overview of the main PD-1/PD-L1 inhibitors' combination approaches under clinical investigation in non-oncogene addicted, metastatic NSCLC patients, including checkpoints (other than CTLA-4) as well as "immune-metabolism" modulators, DNA repair pathway inhibitors, antiangiogenic agents, cytokines, and a new generation of vaccines, with the final aim of identifying the most promising options on the horizon.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
ImmunoTargets and therapy - 10(2021) vom: 20., Seite 9-26 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Passiglia, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Combinations |
|---|
| Anmerkungen: |
Date Revised 19.09.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/ITT.S253581 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321351339 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321351339 | ||
| 003 | DE-627 | ||
| 005 | 20231225175625.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/ITT.S253581 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1071.xml |
| 035 | |a (DE-627)NLM321351339 | ||
| 035 | |a (NLM)33575224 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Passiglia, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC |b New Options on the Horizon? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.09.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 Passiglia et al. | ||
| 520 | |a The therapeutic targeting of the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) axis marked a milestone in the treatment of non-small cell lung cancer (NSCLC), leading to unprecedented response duration and long-term survival for a relevant subgroup of patients affected by non-oncogene-addicted, metastatic disease. However, the biological heterogeneity as well as the occurrence of innate/acquired resistance are well-known phenomena which significantly affect the therapeutic response to immunotherapy. To date, we are moving towards the second phase of the "immune-revolution", characterized by the advent of new immune-checkpoint inhibitors combinations, aiming to target the main resistance pathways and ultimately increase the number of NSCLC patients who may derive long-term clinical benefit from immunotherapy. In this review, we provide an updated and comprehensive overview of the main PD-1/PD-L1 inhibitors' combination approaches under clinical investigation in non-oncogene addicted, metastatic NSCLC patients, including checkpoints (other than CTLA-4) as well as "immune-metabolism" modulators, DNA repair pathway inhibitors, antiangiogenic agents, cytokines, and a new generation of vaccines, with the final aim of identifying the most promising options on the horizon | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a PD-1/PD-L1 | |
| 650 | 4 | |a combinations | |
| 650 | 4 | |a immune-checkpoint | |
| 650 | 4 | |a non-small cell lung cancer | |
| 650 | 4 | |a resistance | |
| 700 | 1 | |a Reale, Maria Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Cetoretta, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Novello, Silvia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ImmunoTargets and therapy |d 2012 |g 10(2021) vom: 20., Seite 9-26 |w (DE-627)NLM237903814 |x 2253-1556 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g day:20 |g pages:9-26 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/ITT.S253581 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |b 20 |h 9-26 | ||